

REMARKS

Claims 1-27 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 1-24, drawn to a composition comprising sertaconazole;

Group II, claim 25, drawn to a process of making a pharmaceutically acceptable dosage form; and

Group III, claims 26-27, drawn to a method for treatment of vulvovaginal candidiasis of the vagina.


For the purpose of examination of the present application, Applicants elect, with traverse, Group I, Claims 1-24. Claim 25 [Group II] is an improper "use" claim and will be amended or cancelled in reply to the Examiner's next Communication. However, claims 26 and 27 [Group III] should be eligible for rejoinder upon allowance of the elected invention. See MPEP "821.04(b) Rejoinder of Process Requiring an Allowable Product [R-5]."

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Marc S. Weiner, Registration No. 32,181 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: FEB 13 2008

Respectfully submitted,

By 
Marc S. Weiner
Registration No.: 32,181
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant